Wave Life Sciences (WVE) is soaring 130.57 percent, up $9.78 to $17.27 on Monday, after announcing strong interim results from the lowest therapeutic cohort of its first-in-human INLIGHT trial for WVE-007, an investigational obesity treatment.
Wave Life Sciences is currently trading at $17.27 compared with a previous close of $7.49 on the Nasdaq. The stock opened at $12.82 and has traded between $12.72 and $18.80 so far today, with volume at 112,108,555 shares.
The 52-week range stands at $5.28 to $18.80.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.